Tag: expenses

PRESS RELEASE
Nantes, June 19th 2026

Phoenix, AZ, June 18, 2026 (GLOBE NEWSWIRE) -- InnSuites Hospitality Trust (NYSE American: IHT) achieved Fiscal First Quarter Consolidated Net Income profitability of $74,702, which is a modest improvement of $35,672, over the prior year Fiscal First Quarter. IHT reported record Hotel Revenue results of approximately $2.2 million in the Fiscal First Quarter of 2027 (February 1, 2026, to April 30, 2026).

WHEATON, Ill., June 18, 2026 (GLOBE NEWSWIRE) -- Innovator Capital Management, LLC (“Innovator”), the investment adviser for the Innovator Gradient Tactical Rotation Strategy ETF and Innovator Hedged Nasdaq-100 ETF (each, a “Fund” and collectively, the “Funds”), announced today that the Funds’ Board of Trustees, at the recommendation of Innovator, has approved a plan of liquidation for each Fund (collectively, the “Plans”). Under the Plans, which are effective as of June 17, 2026, the Funds will begin the process of liquidating portfolio assets and unwinding their affairs in an orderly fashion over time. The Plans are not subject to shareholder approval.

Creates a scaled BDC positioned for growth while maintaining industry leading credit quality and portfolio yield

REYKJAVIK, ICELAND (June 18, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the closing on June 17, 2026 of its previously announced underwritten public offering (the “Offering”) of 26,066,667 of its ordinary shares at an offering price of $3.75 per share, which includes 3,400,000 ordinary shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional ordinary shares in the Offering. All ordinary shares sold in the Offering were offered by Alvotech. Before deducting the underwriting discounts and commissions and offering expenses, the aggregate gross proceeds to the Company were approximately $98 million.

BRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced the pricing of an underwritten public offering of 7,700,000 American Depositary Shares (“ADSs”), each representing two ordinary shares of the Company, at a public offering price of $29.35 per ADS. In addition, Legend Biotech has granted the underwriters a 30-day option to purchase up to an additional 1,155,000 ADSs at the public offering price, less underwriting discounts and commissions. All of the ADSs are being offered by Legend Biotech. The gross proceeds to Legend Biotech from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Legend Biotech, are expected to be approximately $226 million, excluding any proceeds from the exercise of the underwriters’ option to purchase additional ADSs. The offering is expected to close on June 23, 2026, subject to customary closing conditions.